Finance

Lists
CHRS:NASDAQ
Coherus Oncology Inc
1,07 USD
0,00%
(0,00) 1D
9-окт., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHRS...
Open
1,06 USD
High
1,12 USD
Low
1,05 USD
Mkt. cap
165,32 млн
Avg. vol.
1,35 млн
Volume
0,00
52-wk high
2,62 USD
52-wk low
0,97 USD
EPS
-1,03 USD
Beta
0,98
Shares outstanding
154,50 млн
No. of employees
144
Open
1,06 USD
High
1,12 USD
Low
1,05 USD
Mkt. cap
165,32 млн
Avg. vol.
1,35 млн
Volume
0,00
52-wk high
2,62 USD
52-wk low
0,97 USD
EPS
-1,03 USD
Beta
0,98
Shares outstanding
154,50 млн
No. of employees
144
News stories
From web sources and news partners
About Coherus Oncology Inc
CEODennis Lanfear
Employees144
Founded2010
HeadquartersРедвуд Сити, Калифорния, Америка Кошмо Штаттары
Sector-
Websitecoherus.com
Analyst ratings
Based on 4 analysts giving stock ratings to CHRS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CHRS in the last 3 months.
Highest
Current 1,07 USD
10,00 USD (+834,58%)
Average
7,75 USD (+624,30%)
Lowest
4,00 USD (+273,83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
7,00 USD
+554,2%
09/21/2026
Jason McCarthy
Maxim Group
Buy
Maintained
4,00 USD
+273,8%
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
10,00 USD
+834,6%
08/06/2026
Jay Olson
Oppenheimer
Buy
Maintained
10,00 USD
+834,6%
08/06/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
-
-
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
11,57 млн
12,75 млн
12,31 млн
14,31 млн
Cost of goods sold
3,72 млн
4,04 млн
3,81 млн
4,24 млн
Cost of revenue
3,72 млн
4,04 млн
3,81 млн
4,24 млн
Research and development expenses
27,25 млн
30,97 млн
21,54 млн
21,45 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
22,83 млн
21,01 млн
23,10 млн
20,95 млн
Operating expense
50,08 млн
51,98 млн
44,65 млн
42,40 млн
Total operating expenses
53,80 млн
56,03 млн
48,46 млн
46,64 млн
Operating income
-42,23 млн
-43,28 млн
-36,15 млн
-32,33 млн
Other non operating income
2,14 млн
-5,22 млн
1,40 млн
1,31 млн
EBT including unusual items
-44,52 млн
-46,35 млн
-36,94 млн
-33,35 млн
EBT excluding unusual items
-42,42 млн
-43,75 млн
-36,94 млн
-33,35 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-35,53 млн
-37,64 млн
-38,33 млн
-20,63 млн
Net profit margin
-307,07%
-295,29%
-311,35%
-144,20%
Earnings per share
-0,33
-0,34
-0,25
-0,19
Interest and investment income
-
7,00 млн
-
-
Interest expense
-2,32 млн
-2,25 млн
-2,19 млн
-2,32 млн
Net interest expenses
-2,32 млн
4,75 млн
-2,19 млн
-2,32 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,27 млн
-42,38 млн
-35,27 млн
-31,47 млн
Gain or loss from assets sale
-
-338,32 млн
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору